The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position

Ji Young Mun, Robert W. Kensler, Samantha P. Harris, Roger Craig

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Mutations in cardiac myosin binding protein C (cMyBP-C), a thick filament protein that modulates contraction of the heart, are a leading cause of hypertrophic cardiomyopathy (HCM). Electron microscopy and 3D reconstruction of thin filaments decorated with cMyBP-C N-terminal fragments suggest that one mechanism of this modulation involves the interaction of cMyBP-C's N-terminal domains with thin filaments to enhance their Ca2+-sensitivity by displacement of tropomyosin from its blocked (low Ca2+) to its closed (high Ca2+) position. The extent of this tropomyosin shift is reduced when cMyBP-C N-terminal domains are phosphorylated. In the current study, we have examined L348P, a sequence variant of cMyBP-C first identified in a screen of patients with HCM. In L348P, leucine 348 is replaced by proline in cMyBP-C's regulatory M-domain, resulting in an increase in cMyBP-C's ability to enhance thin filament Ca2+-sensitization. Our goal here was to determine the structural basis for this enhancement by carrying out 3D reconstruction of thin filaments decorated with L348P-mutant cMyBP-C. When thin filaments were decorated with wild type N-terminal domains at low Ca2+, tropomyosin moved from the blocked to the closed position, as found previously. In contrast, the L348P mutant caused a significantly larger tropomyosin shift, to approximately the open position, consistent with its enhancement of Ca2+-sensitization. Phosphorylated wild type fragments showed a smaller shift than unphosphorylated fragments, whereas the shift induced by the L348P mutant was not affected by phosphorylation. We conclude that the L348P mutation causes a gain of function by enhancing tropomyosin displacement on the thin filament in a phosphorylation-independent way.

Original languageEnglish (US)
Pages (from-to)141-147
Number of pages7
JournalJournal of Molecular and Cellular Cardiology
Volume91
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Cardiac Myosins
Tropomyosin
Hypertrophic Cardiomyopathy
Phosphorylation
Mutation
Proline
Leucine
Electron Microscopy
myosin-binding protein C
Proteins

Keywords

  • Cardiac muscle
  • CMyBP-C
  • Electron microscopy
  • Hypertrophic cardiomyopathy
  • Myosin binding protein C
  • Thin filament

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position. / Mun, Ji Young; Kensler, Robert W.; Harris, Samantha P.; Craig, Roger.

In: Journal of Molecular and Cellular Cardiology, Vol. 91, 01.02.2016, p. 141-147.

Research output: Contribution to journalArticle

Mun, Ji Young ; Kensler, Robert W. ; Harris, Samantha P. ; Craig, Roger. / The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position. In: Journal of Molecular and Cellular Cardiology. 2016 ; Vol. 91. pp. 141-147.
@article{13d690ec15614d439552e75f3c29c215,
title = "The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position",
abstract = "Mutations in cardiac myosin binding protein C (cMyBP-C), a thick filament protein that modulates contraction of the heart, are a leading cause of hypertrophic cardiomyopathy (HCM). Electron microscopy and 3D reconstruction of thin filaments decorated with cMyBP-C N-terminal fragments suggest that one mechanism of this modulation involves the interaction of cMyBP-C's N-terminal domains with thin filaments to enhance their Ca2+-sensitivity by displacement of tropomyosin from its blocked (low Ca2+) to its closed (high Ca2+) position. The extent of this tropomyosin shift is reduced when cMyBP-C N-terminal domains are phosphorylated. In the current study, we have examined L348P, a sequence variant of cMyBP-C first identified in a screen of patients with HCM. In L348P, leucine 348 is replaced by proline in cMyBP-C's regulatory M-domain, resulting in an increase in cMyBP-C's ability to enhance thin filament Ca2+-sensitization. Our goal here was to determine the structural basis for this enhancement by carrying out 3D reconstruction of thin filaments decorated with L348P-mutant cMyBP-C. When thin filaments were decorated with wild type N-terminal domains at low Ca2+, tropomyosin moved from the blocked to the closed position, as found previously. In contrast, the L348P mutant caused a significantly larger tropomyosin shift, to approximately the open position, consistent with its enhancement of Ca2+-sensitization. Phosphorylated wild type fragments showed a smaller shift than unphosphorylated fragments, whereas the shift induced by the L348P mutant was not affected by phosphorylation. We conclude that the L348P mutation causes a gain of function by enhancing tropomyosin displacement on the thin filament in a phosphorylation-independent way.",
keywords = "Cardiac muscle, CMyBP-C, Electron microscopy, Hypertrophic cardiomyopathy, Myosin binding protein C, Thin filament",
author = "Mun, {Ji Young} and Kensler, {Robert W.} and Harris, {Samantha P.} and Roger Craig",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.yjmcc.2015.12.014",
language = "English (US)",
volume = "91",
pages = "141--147",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position

AU - Mun, Ji Young

AU - Kensler, Robert W.

AU - Harris, Samantha P.

AU - Craig, Roger

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Mutations in cardiac myosin binding protein C (cMyBP-C), a thick filament protein that modulates contraction of the heart, are a leading cause of hypertrophic cardiomyopathy (HCM). Electron microscopy and 3D reconstruction of thin filaments decorated with cMyBP-C N-terminal fragments suggest that one mechanism of this modulation involves the interaction of cMyBP-C's N-terminal domains with thin filaments to enhance their Ca2+-sensitivity by displacement of tropomyosin from its blocked (low Ca2+) to its closed (high Ca2+) position. The extent of this tropomyosin shift is reduced when cMyBP-C N-terminal domains are phosphorylated. In the current study, we have examined L348P, a sequence variant of cMyBP-C first identified in a screen of patients with HCM. In L348P, leucine 348 is replaced by proline in cMyBP-C's regulatory M-domain, resulting in an increase in cMyBP-C's ability to enhance thin filament Ca2+-sensitization. Our goal here was to determine the structural basis for this enhancement by carrying out 3D reconstruction of thin filaments decorated with L348P-mutant cMyBP-C. When thin filaments were decorated with wild type N-terminal domains at low Ca2+, tropomyosin moved from the blocked to the closed position, as found previously. In contrast, the L348P mutant caused a significantly larger tropomyosin shift, to approximately the open position, consistent with its enhancement of Ca2+-sensitization. Phosphorylated wild type fragments showed a smaller shift than unphosphorylated fragments, whereas the shift induced by the L348P mutant was not affected by phosphorylation. We conclude that the L348P mutation causes a gain of function by enhancing tropomyosin displacement on the thin filament in a phosphorylation-independent way.

AB - Mutations in cardiac myosin binding protein C (cMyBP-C), a thick filament protein that modulates contraction of the heart, are a leading cause of hypertrophic cardiomyopathy (HCM). Electron microscopy and 3D reconstruction of thin filaments decorated with cMyBP-C N-terminal fragments suggest that one mechanism of this modulation involves the interaction of cMyBP-C's N-terminal domains with thin filaments to enhance their Ca2+-sensitivity by displacement of tropomyosin from its blocked (low Ca2+) to its closed (high Ca2+) position. The extent of this tropomyosin shift is reduced when cMyBP-C N-terminal domains are phosphorylated. In the current study, we have examined L348P, a sequence variant of cMyBP-C first identified in a screen of patients with HCM. In L348P, leucine 348 is replaced by proline in cMyBP-C's regulatory M-domain, resulting in an increase in cMyBP-C's ability to enhance thin filament Ca2+-sensitization. Our goal here was to determine the structural basis for this enhancement by carrying out 3D reconstruction of thin filaments decorated with L348P-mutant cMyBP-C. When thin filaments were decorated with wild type N-terminal domains at low Ca2+, tropomyosin moved from the blocked to the closed position, as found previously. In contrast, the L348P mutant caused a significantly larger tropomyosin shift, to approximately the open position, consistent with its enhancement of Ca2+-sensitization. Phosphorylated wild type fragments showed a smaller shift than unphosphorylated fragments, whereas the shift induced by the L348P mutant was not affected by phosphorylation. We conclude that the L348P mutation causes a gain of function by enhancing tropomyosin displacement on the thin filament in a phosphorylation-independent way.

KW - Cardiac muscle

KW - CMyBP-C

KW - Electron microscopy

KW - Hypertrophic cardiomyopathy

KW - Myosin binding protein C

KW - Thin filament

UR - http://www.scopus.com/inward/record.url?scp=84953396946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953396946&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2015.12.014

DO - 10.1016/j.yjmcc.2015.12.014

M3 - Article

C2 - 26718724

AN - SCOPUS:84953396946

VL - 91

SP - 141

EP - 147

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -